News

Zacks Small Cap Research on MSN12h
MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…
(NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity.
Science Daily7h
Sharp uptake in use of new weight loss and glucose-lowering medications
Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.
American Council on Science and Health11h
Every Picture Tells A Story - GLP-1s Reframe Obesity
As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...
Drug Store News10h
What retailers should know about consumers taking GLP-1s for weight loss
An Acosta Group study finds that 76% of those who discontinued GLP-1s are eating the same amount or less and many report ...